AstraZeneca discontinues Phase III trials of Stabilizer-CKD and Dialize-Outcomes

STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme

Merck to acquire Caraway Therapeutics

Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases

Evive Biotech and Acrotech Biopharma receive FDA approval of Ryzneuta

AskBio announces first patient randomized in Phase 1 Trial of AB-1005

Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels

USFDA approves Pfizer’s Velsipity for adults with Ulcerative Colitis

Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials

Ichnos Sciences inks agreement with Astria Therapeutics for OX40 antagonist monoclonal antibody portfolio

Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications

Biocon signs commercialization agreement with Juno Pharmaceuticals in Canada

Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market

Emmes acquires VaxTRIALS

VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth

Emmes appoints Matt Bond as CFO

His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy

Menarini strengthens its presence in aesthetic dermatology in India

The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation